Global Blood Therapeutics/Pfizer
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. As of October 5, 2022, GBT is a subsidiary of Pfizer. For more information, visit www.gbt.com or www.pfizer.com.